<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161443">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01896895</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ60201_3074_1</org_study_id>
    <secondary_id>2012-004821-26</secondary_id>
    <nct_id>NCT01896895</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid</brief_title>
  <official_title>Prospective, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of Two Different Doses of NT 201 in Botulinum Toxin Treatment-naïve Subjects With Blepharospasm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <authority>Malaysia: Ministry of Health</authority>
    <authority>India: Drugs Controller General of India</authority>
    <authority>Sri Lanka: Ministry of Healthcare &amp; Nutrition</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 3 study will serve to collect efficacy and safety data of two different doses of
      NT 201 in subjects suffering from Bilateral Blephorasm (BEB) who are BTX treatment-naïve.

      In this study, BTX treatment-naïve subjects are defined as those who have not received BTX
      treatment within the last 12 months for the treatment of BEB. This definition aims to avoid
      bias by comparison of treatment effects in the subject's assessments. Furthermore, this
      study will substantiate the existing efficacy and safety database for the indication BEB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects to receive one injection with NT 201 or placebo at baseline of the
      placebo-controlled first cycle. Thereafter, all subjects entering the Open-Label Extension
      Period (OLEX) to receive a second injection of NT 201 (second injection cycle).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in Jankovic rating scale (JRS) severity subscore determined at V4 (Week 6)</measure>
    <time_frame>Baseline to week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Jankovic Rating Scale (JRS) is used for classification of the patient's individual symptoms of blepharospasm and for determination of the therapeutic efficacy of study medication. The JRS-Severity sub-score is used, which ranges from 0 (=absence of severity) to 4 (=maximum severity).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Blepharospasm Disability Index (BSDI) score at Visit 4 (week 6)</measure>
    <time_frame>Baseline to week 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Blepharospasm Disability Index is a disease specific scale for subject functional self assessment of impairment of specific activities of daily living caused by blepharospasm. The BSDI consists of six items (driving a vehicle; reading; watching TV; shopping; getting about on foot (walking); doing everyday activities), each ranges from 0 (=no impairment) to 4 (=no longer possible due to illness). The BSDI will be assessed before rating the JRS for unbiased information by subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Evaluation of Global Response [PEGR] at final visit of Main Period (V5 -up to week 20)</measure>
    <time_frame>Up to week 20</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PEGR is a descriptive subjective 9-point response scale ranging from &quot;complete abolishment of signs and symptoms&quot; (value=+4) down to &quot;very marked worsening&quot; (value=-4).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bilateral Blepharospasm (BEB)</condition>
  <arm_group>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) 25U per eye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main Period: one injection session, 25 Units per eye. Open-Label Extension: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) 12.5U per eye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main Period: one injection session, 12.5 Units per eye. Open-Label Extension Period: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session.
Open-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IncobulinumtoxinA (Xeomin), 25 Units</intervention_name>
    <description>IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.</description>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) 25U per eye</arm_group_label>
    <other_name>NT 201</other_name>
    <other_name>Xeomin</other_name>
    <other_name>Botulinum toxin type A (150 kiloDalton), free from complexing proteins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IncobotulinumtoxinA (Xeomin), 12.5 Units</intervention_name>
    <description>IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.</description>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) 12.5U per eye</arm_group_label>
    <other_name>NT 201</other_name>
    <other_name>Xeomin</other_name>
    <other_name>Botulinum toxin type A (150 kiloDalton), free from complexing proteins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IncobotulinumtoxinA (Xeomin), 35 Units</intervention_name>
    <description>IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Open-Label Extension: up to 35 Units per eye.</description>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) 25U per eye</arm_group_label>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) 12.5U per eye</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NT 201</other_name>
    <other_name>Xeomin</other_name>
    <other_name>Botulinum toxin type A (150 kiloDalton), free from complexing proteins</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female out-patients age ≥ 18 and ≤ 80 years.

          -  A clinical diagnosis of bilateral BEB characterized by spontaneous, spasmodic,
             intermittent or persistent involuntary contractions of orbicular oculi muscles.

          -  A need for injection of BTX defined as a Jankovic Rating Scale [JRS] severity
             subscore ≥ 2.

          -  Treatment-naïve subject defined as at least 12 months without BTX of any serotype for
             the treatment of BEB before administration of IP.

        Exclusion Criteria:

          -  Subject with any previous unsuccessful treatment with BTX of any serotype for the
             treatment of BEB.

          -  Atypical variant of BEB (e.g., apraxia of the eyelid opening) caused by inhibition of
             levator palpebrae muscle.

          -  Neuroleptic-induced blepharospasm.

          -  Myotomy or denervation surgery in the affected muscles (e.g., peripheral denervation,
             spinal cord stimulation) and surgery in the upper face.

          -  Generalized disorders of muscles activity (e.g., myasthenia gravis in particular
             ocularis, Lambert-Eaton-Syndrome, amyotrophic lateral sclerosis) or any other
             significant neuromuscular dysfunction which might interfere with the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Pharmaceuticals GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Public Disclosure Manager</last_name>
    <email>clinicaltrials@merz.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Merz Investigational Site #030001</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #030002</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #030004</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #030003</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #060004</name>
      <address>
        <city>Kota Kinabalu</city>
        <state>Sabah</state>
        <zip>88586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #060002</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #060003</name>
      <address>
        <city>Selangor</city>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #094004</name>
      <address>
        <city>Anuradhapura</city>
        <zip>50000</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #094005</name>
      <address>
        <city>Colombo</city>
        <zip>10350</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #094003</name>
      <address>
        <city>Colombo</city>
        <zip>10</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #094001</name>
      <address>
        <city>Colombo</city>
        <zip>07</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merz Investigational Site #094002</name>
      <address>
        <city>Nugegoda</city>
        <zip>10250</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Malaysia</country>
    <country>Sri Lanka</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>July 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blepharospasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
